Welcome to LookChem.com Sign In|Join Free

CAS

  • or

886362-90-9

Post Buying Request

886362-90-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

886362-90-9 Usage

General Description

3-[2-(2-ethoxycarbonyl-ethoxy)-ethoxy]-propionic acid, also known as Etodolac, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used to relieve pain and reduce inflammation associated with conditions such as arthritis and other musculoskeletal disorders. The compound works by inhibiting the production of prostaglandins, which play a key role in causing pain, swelling, and fever. Etodolac is a derivative of pyranocarboxylic acid and is primarily metabolized in the liver. It is available in various formulations, including tablets, extended-release tablets, and oral suspension, and is typically administered orally. However, it may also be used topically in veterinary medicine. Etodolac is generally well-tolerated, but it may cause side effects such as stomach pain, indigestion, and dizziness, and is not recommended for use in individuals with a history of allergic reactions to NSAIDs or those with a history of peptic ulcers or gastrointestinal bleeding.

Check Digit Verification of cas no

The CAS Registry Mumber 886362-90-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,3,6 and 2 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 886362-90:
(8*8)+(7*8)+(6*6)+(5*3)+(4*6)+(3*2)+(2*9)+(1*0)=219
219 % 10 = 9
So 886362-90-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H18O6/c1-2-16-10(13)4-6-15-8-7-14-5-3-9(11)12/h2-8H2,1H3,(H,11,12)

886362-90-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-(2-(3-Ethoxy-3-oxopropoxy)ethoxy)propanoic acid

1.2 Other means of identification

Product number -
Other names 3-[2-(3-ethoxy-3-oxopropoxy)ethoxy]propanoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:886362-90-9 SDS

886362-90-9Downstream Products

886362-90-9Relevant articles and documents

Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)

Dragovich, Peter S.,Adhikari, Pragya,Blake, Robert A.,Blaquiere, Nicole,Chen, Jinhua,Cheng, Yun-Xing,den Besten, Willem,Han, Jinping,Hartman, Steven J.,He, Jintang,He, Mingtao,Rei Ingalla, Ellen,Kamath, Amrita V.,Kleinheinz, Tracy,Lai, Tommy,Leipold, Douglas D.,Li, Chun Sing,Liu, Qi,Lu, Jiawei,Lu, Ying,Meng, Fanwei,Meng, Lingyao,Ng, Carl,Peng, Kaishan,Lewis Phillips, Gail,Pillow, Thomas H.,Rowntree, Rebecca K.,Sadowsky, Jack D.,Sampath, Deepak,Staben, Leanna,Staben, Steven T.,Wai, John,Wan, Kunpeng,Wang, Xinxin,Wei, BinQing,Wertz, Ingrid E.,Xin, Jianfeng,Xu, Keyang,Yao, Hui,Zang, Richard,Zhang, Donglu,Zhou, Hao,Zhao, Yongxin

supporting information, (2020/01/08)

Chimeric molecules which effect intracellular degradation of target proteins via E3 ligase-mediated ubiquitination (e.g., PROTACs) are currently of high interest in medicinal chemistry. However, these entities are relatively large compounds that often possess molecular characteristics which may compromise oral bioavailability, solubility, and/or in vivo pharmacokinetic properties. Accordingly, we explored whether conjugation of chimeric degraders to monoclonal antibodies using technologies originally developed for cytotoxic payloads might provide alternate delivery options for these novel agents. In this report we describe the construction of several degrader-antibody conjugates comprised of two distinct ERα-targeting degrader entities and three independent ADC linker modalities. We subsequently demonstrate the antigen-dependent delivery to MCF7-neo/HER2 cells of the degrader payloads that are incorporated into these conjugates. We also provide evidence for efficient intracellular degrader release from one of the employed linkers. In addition, preliminary data are described which suggest that reasonably favorable in vivo stability properties are associated with the linkers utilized to construct the degrader conjugates.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 886362-90-9